Clinical Trial Update: A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study of clemastine fumarate plus engineered sound to treat age-related central auditory processing disorder; recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Auditory Processing Disorder
• Hearing Loss
• Sensorineural Hearing Loss

Drugs mentioned

• Clemastine Fumarate (clemastine fumarate)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Central Auditory Processing Disorder, Hearing Impaired (Partially) | Phase 1, Phase 2 | Status: RECRUITING